EBRO 2017

Tra

6 RCTs, 2822 patients Endpoint: 10-year efficacy of CDRT vs HDRT

- OS = no difference - PCSS = no difference - Better BFS : 34.0 vs. 24.7 % (p < 0.00001).

- Toxicity: HDRT significantly increased: - late Grade 2+ GI tox (28.0 vs. 18.6 %, p < 0.0001) - late G2+ GU toxicity (22.6 vs. 19.5 %, p = 0.04).

Hou Z et al., J Cancer Res Clin Oncol. 2015 Jun;141(6):1063-71